Haemonetics Corporation (NYSE:HAE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $78.8889.

A number of brokerages have commented on HAE. JPMorgan Chase & Co. decreased their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Mizuho upped their target price on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Citigroup reissued a “neutral” rating on shares of Haemonetics in a research report on Wednesday, July 8th. Barrington Research lowered their price objective on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Finally, Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $72.00 to $80.00 in a research note on Friday, May 22nd.

Haemonetics Trading Down 0.7%

Shares of NYSE HAE opened at $77.49 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a market cap of $3.52 billion, a price-to-earnings ratio of 38.36, a P/E/G ratio of 1.57 and a beta of 0.52. The business has a fifty day simple moving average of $72.31 and a 200-day simple moving average of $66.08.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter last year, the business posted $1.24 EPS. Haemonetics’s revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts predict that Haemonetics will post 5.21 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

Several large investors have recently made changes to their positions in HAE. AQR Capital Management LLC raised its position in Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after acquiring an additional 1,678,630 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after acquiring an additional 1,254,035 shares during the last quarter. Millennium Management LLC grew its position in Haemonetics by 4,296.3% in the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after acquiring an additional 755,592 shares in the last quarter. North Peak Capital Management LLC grew its position in Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after acquiring an additional 740,626 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Haemonetics during the 3rd quarter worth $15,703,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.